Jefferies Financial Group Inc. Raises Stock Position in Cencora, Inc. (NYSE:COR)

Jefferies Financial Group Inc. increased its position in shares of Cencora, Inc. (NYSE:COR) by 61.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 9,375 shares of the company’s stock after purchasing an additional 3,574 shares during the period. Jefferies Financial Group Inc.’s holdings in Cencora were worth $2,106,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Czech National Bank raised its position in shares of Cencora by 7.0% in the 4th quarter. Czech National Bank now owns 38,025 shares of the company’s stock valued at $8,543,000 after purchasing an additional 2,489 shares during the last quarter. Trust Co. of Toledo NA OH increased its holdings in Cencora by 32.6% in the 4th quarter. Trust Co. of Toledo NA OH now owns 1,358 shares of the company’s stock worth $305,000 after acquiring an additional 334 shares in the last quarter. City State Bank increased its stake in Cencora by 19.3% during the 4th quarter. City State Bank now owns 618 shares of the company’s stock worth $139,000 after buying an additional 100 shares in the last quarter. Wedmont Private Capital grew its position in shares of Cencora by 33.1% in the fourth quarter. Wedmont Private Capital now owns 2,453 shares of the company’s stock valued at $579,000 after purchasing an additional 610 shares in the last quarter. Finally, Cooper Financial Group grew its holdings in shares of Cencora by 8.1% in the fourth quarter. Cooper Financial Group now owns 3,211 shares of the company’s stock valued at $721,000 after purchasing an additional 240 shares during the period. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Price Performance

NYSE COR opened at $279.00 on Wednesday. The company has a market cap of $54.10 billion, a PE ratio of 39.69, a PEG ratio of 1.31 and a beta of 0.60. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $309.35. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. The stock’s 50-day moving average price is $277.02 and its two-hundred day moving average price is $253.87.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, beating the consensus estimate of $4.07 by $0.35. The company had revenue of $75.50 billion for the quarter, compared to the consensus estimate of $75.41 billion. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the company posted $3.80 earnings per share. On average, analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 2nd. Shareholders of record on Friday, May 16th will be paid a $0.55 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $2.20 dividend on an annualized basis and a yield of 0.79%. Cencora’s payout ratio is 25.52%.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on COR. Evercore ISI increased their target price on shares of Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research note on Thursday, February 6th. Bank of America raised their price target on shares of Cencora from $270.00 to $285.00 and gave the company a “neutral” rating in a research report on Friday, April 11th. Citigroup lifted their price objective on Cencora from $330.00 to $355.00 and gave the company a “buy” rating in a research note on Thursday, May 8th. StockNews.com upgraded Cencora from a “hold” rating to a “buy” rating in a research note on Wednesday, March 12th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a report on Friday, January 24th. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $301.18.

Insider Buying and Selling

In related news, EVP Silvana Battaglia sold 5,000 shares of the firm’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the sale, the executive vice president now directly owns 15,374 shares in the company, valued at approximately $3,724,197.76. This trade represents a 24.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Elizabeth S. Campbell sold 4,127 shares of the stock in a transaction on Monday, March 24th. The stock was sold at an average price of $268.28, for a total value of $1,107,191.56. Following the transaction, the executive vice president now owns 14,665 shares in the company, valued at $3,934,326.20. The trade was a 21.96% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 50,223 shares of company stock valued at $13,580,967. Company insiders own 10.80% of the company’s stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.